CSL upgrades profit guidance, shares jump

CSL CEO Paul Perreault/ Listcorp.

Shares in biotech manufacturer CSL are more than 4% higher this morning after the company upgraded its full-year profit guidance.

CSL now forecasts that net profits in the 2018 financial year reach between $US1.68 billion ($2.23 billion) to $US1.71 billion on a constant currency basis.

The blood-products company — which has carried out one of Australia’s most successful off-shore strategies — applies a constant currency basis to remove the effect of exchange rate movements.

CSL now generates about 90% of its revenue offshore. This month, it became one of the top 5 larges companies on the ASX by market capitalisation.

It’s the second profit upgrade CSL has announced this year, after providing guidance in February for full-year profit of between $US1.55 — $US1.60 billion.

CEO Paul Perreault called the results pleasing, and highlighted particular success for two product lines used in the treatment of hemophilia and angioedema — a skin condition which causes swelling.

“I am pleased to report an improved Company outlook for the financial year, underpinned by a confluence of positive outcomes as we work to deliver on our strategy,” Perreault said.

“Of particular note has been a positive product and geographic sales mix shift. The phasing of investments in some of our clinical trials has also yielded a positive financial variance.”

Perreault said the company’s flu treatment products were also performing well after severe influenza season in the northern hemisphere.

A short time ago, CSL shares had pushed above $180 in morning trade:

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.